The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Tanashyan M.M.

Neurology Research Center, Moscow, Russia

Lagoda O.V.

Research Centre of Neurology, Moscow, Russia

Evdokimenko A.N.

Research Center of Neurology, Moscow, Russia

Shabalina A.A.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Raskurazhev A.A.

Neurology Research Center, Moscow, Russia

Cerebral atherosclerosis: a biomarker profile

Authors:

Tanashyan M.M., Lagoda O.V., Evdokimenko A.N., Shabalina A.A., Raskurazhev A.A.

More about the authors

Read: 2351 times


To cite this article:

Tanashyan MM, Lagoda OV, Evdokimenko AN, Shabalina AA, Raskurazhev AA. Cerebral atherosclerosis: a biomarker profile. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):23‑29. (In Russ.)
https://doi.org/10.17116/jnevro20181185123

Recommended articles:
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
New aspe­cts of psoriasis pathogenesis: meta­bolomic profiling in dermatology. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):526-531
Dyna­mics of motor and functional diso­rders in the early reco­very period after ischemic stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):13-22
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
Differentiated approach to cognitive reha­bilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11

References:

  1. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. Journal of Internal Medicine. 2014;276(6):618-632. https://doi.org/10.1111/joim.12296
  2. den Hartog AG, Achterberg S, Moll FL, Kappelle LJ, Visseren FLJ, van der Graaf Y, Algra A, SMART Study Group. Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinically manifest arterial disease. Stroke. 2013;44:1002-1007. https://doi.org/10.1161/STROKEAHA.111.669267
  3. Tanashyan MM, Suslina ZA, Ionova VG, Domashenko MA, Orlov SV, Chechetkin AO, Pleshkova MYu. Endothelium function state in patients with ischemic insult at different forms of carotid arteries atherosclerotic lesion. Nevrologicheskii vestnik. 2007;39(1):12-16. (In Russ.)
  4. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(2):168-175. https://doi.org/10.1161/01.atv.0000051384.43104.fc
  5. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circulation Research. 2001;88:756-762. https://doi.org/10.1161/hh0801.089861
  6. Freedman JE, Sauter R, Battinelli EM, Ault C., Knowles C, Huang PL, Loscalzo J. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circulation Research. 1999;84:1416-1421. https://doi.org/10.1161/01.res.84.12.1416
  7. Tsao PS, Theilmer G, Singer AH, Leung LL, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology. 1994;14:1529-1533. https://doi.org/10.1161/01.atv.14.10.1529
  8. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circulation Research. 1995;76:980-986. https://doi.org/10.1161/01.res.76.6.980
  9. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshiata A. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:1456-1464. https://doi.org/10.1161/01.atv.18.9.1456
  10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143. https://doi.org/10.1161/hc0902.104353\
  11. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Molecular Cell. 1998;2:275-281. https://doi.org/10.1016/s1097-2765(00)80139-2
  12. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897. https://doi.org/10.1038/29788
  13. Landmesser U, Hornig B, Drexler H. Endothelial Function: A Critical Determinant in Atherosclerosis? Circulation. 2004;109:II-27-II-33. https://doi.org/10.1161/01.cir.0000129501.88485.1f
  14. Gumanova NG, Teplova NV, Ryabchenko AU, Denisov EN. Serum nitrate and nitrite levels in patients with hypertension and ischemic stroke depend on diet: a multicenter study. Clinical Biochemistry. 2015;48(1-2):29-32. https://doi.org/10.1016/j.clinbiochem.2014.10.010
  15. Alef MJ, Tzeng E, Zuckerbraun BS. Nitric oxide and nitrite-based therapeutic opportunities in intimal hyperplasia. Nitric Oxide. 2012;26(4):285-294. https://doi.org/10.1016/j.niox.2012.03.014
  16. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C, Hogg N, Schechter AN, Gladwin MT. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. The Journal of Clinical Investigation. 2005;115(8):2099-2107. https://doi.org/10.1172/jci24650
  17. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847. https://doi.org/10.1161/01.cir.98.18.1842
  18. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146. https://doi.org/10.1161/01.cir.99.9.1141
  19. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. American Journal of Cardiology. 2001;88(10):1201-1203. https://doi.org/10.1016/s0002-9149(01)02063-x
  20. Furuki K, Adachi H, Enomoto M, Otsuka M, Fukami A, Kumagae S, Matsuoka H, Nanjo Y, Kakuma T, Imaizumi T. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertension Research. 2008;31:1185-1189. https://doi.org/10.1291/hypres.31.1185
  21. Chirinos JA, David R, Bralley JA, Zea-Diaz H, Munoz-Atahualp E, Corrales-Medina F, Cuba-Bustinza C, Chirinos-Pacheco J, Medina-Lezama J. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. Hypertension. 2008;52:1051-1059. https://doi.org/10.1161/hypertensionaha.108.120352
  22. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis. 2007;191(1):206-210. https://doi.org/10.1016/j.atherosclerosis.2006.03.022
  23. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Mode-Boger SM. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke. 2006;37(8):2024-2029. https://doi.org/10.1161/01.str.0000231640.32543.11
  24. Tanashyan MM, Raskurazhev AA, Shabalina AA, Lagoda OV, Gnedovskaya EV. Biomarkers of cerebral atherosclerosis: the capabilities of early diagnosis and prognosis of individual risk. Annaly klinicheskoi i eksperimental’noi nevrologii. 2015;9(3):20-25. (In Russ.)
  25. Li H, Förstermann U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Current Opinion in Pharmacology. 2013;13(2):161-167. https://doi.org/10.1016/j.coph.2013.01.006
  26. Suslina ZA, Tanashyan MM, Ionova VG. Ishemicheskii insul’t: krov’, sosudistaya stenka, antitromboticheskaya terapiya. M.: Meditsinskaya kniga; 2005. (In Russ.)
  27. Bouch JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18(11):1771-1779. https://doi.org/10.1161/01.atv.18.11.1771
  28. Massot A, Giralt D, Penalba A, Garcia-Berrocoso T, Navarro-Sobrino M, Arenillas JF, Ribo M, Molina CA, Alvarez-Sabin J, Montaner J, Delgado P. Predictive value of ankle-brachial index and PAI-1 in symptomatic intracranial atherosclerotic dis-ease recurrence. Atherosclerosis. 2014;233(1):186-189. https://doi.org/10.1016/j.atherosclerosis.2013.12.034
  29. Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M. Functional Stability of Plasminogen Activator Inhibitor-1. The Scientific World Journal. 2014;2014:1-11. https://doi.org/10.1155/2014/858293
  30. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98(21):2241-2247. https://doi.org/10.1161/01.cir.98.21.2241
  31. Tanashyan MM, Lagoda OV, Gulevskaya TS, Maksyutkina LN, Raskurazhev AA. Progressing cerebral atherosclerosis: clinical, biochemical and morphological aspects. Annaly klinicheskoi i eksperimental’noi nevrologii. 2013;7(4):4-9. (In Russ.)
  32. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D’Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. American Journal of Cardiology. 2004;94(1): 20-24. https://doi.org/10.1016/j.amjcard.2004.03.023

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.